Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemokine (C-X-C motif) ligand 7 (CXCL7)
- Target
- CXCL7
- Molecular classification
- Chemokine, Growth factor, Cytokine, Small-inducible chemokine
01
Overview
Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as pro-platelet basic protein (PPBP), beta-thromboglobulin, and connective tissue-activating peptide III, is a platelet-derived cytokine and growth factor of the CXC chemokine family. Released in large amounts from platelets upon activation, CXCL7 functions as a potent chemoattractant and activator of neutrophils, stimulating several cellular processes such as DNA synthesis, cell division, metabolism, prostaglandin E2 secretion, and extracellular matrix production. It also enhances the secretion of plasminogen activator by synovial cells and exhibits direct antimicrobial properties. CXCL7 is clinically relevant in the context of inflammatory diseases and thrombotic disorders, and its plasma concentration serves as a biomarker for platelet activation and risk of thrombotic events.
- Other names
- Pro-platelet basic proteinPlatelet basic proteinBeta-thromboglobulinConnective tissue-activating peptide IIINeutrophil-activating peptide 2CTAP3CTAP-IIITC1TC2NAP-2LA-PF4TGBTGB1B-TG1SCYB7MDGFLDGFTHBGBTHBGB1Beta-TG
02
Mechanism of action
Indirect antagonism or modulation of its receptors (e.g., CXCR1/CXCR2 blockers can reduce neutrophil recruitment/inflammation) Inhibition of its downstream chemotactic and inflammatory effects
03
Biological functions
Chemoattractant and activator of neutrophilsStimulates DNA synthesis, mitosis, glycolysisPromotes intracellular cAMP accumulation and prostaglandin E2 secretionInduces synthesis of hyaluronic acid and sulfated glycosaminoglycanStimulates plasminogen activator formation/secretion by synovial cellsExhibits antimicrobial (bactericidal and antifungal) activity
04
Disease associations
InflammationCardiovascular disease (thrombosis, thrombocytosis)Erythromelalgia
05
Safety considerations
Targeting CXCL7/PPBP or its pathway may disrupt normal immune response and anti-microbial defensePotential for impaired wound healing or infection if neutrophil chemotaxis is excessively inhibited
06
Interacting drugs
No widely established direct PPBP-targeting drugs; some agents may modulate its receptor CXCR1/CXCR2, or its signaling, but no direct small molecule or biologic drugs against CXCL7/PPBP are in clinical use as of current consensus
07
Biomarkers
Plasma levels of PPBP/Beta-thromboglobulin for thrombosis riskUsed as a diagnostic marker in deep vein thrombosis and in monitoring platelet activation
Beyond the preview
Go deeper on Chemokine (C-X-C motif) ligand 7 (CXCL7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chemokine (C-X-C motif) ligand 7 (CXCL7).